Wilson’s Disease: An Analysis of Health Care Use and Cost Burden of Commercially Insured Adults in the United States
The economic and health care use burdens of Wilson’s disease (WD) are unknown. In this study, we aimed to quantify this health care resource use and economic burden. We performed a retrospective case‐control analysis of individuals in the Truven Health MarketScan Commercial Claims database (2007‐201...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health/LWW
2022-02-01
|
| Series: | Hepatology Communications |
| Online Access: | https://doi.org/10.1002/hep4.1812 |
| _version_ | 1828044848908730368 |
|---|---|
| author | Vinod K. Rustgi Kapil Gupta Christopher Tait Abhishek Bhurwal Savan Kabaria Carolyn Catalano You Li Carlos D. Minacapelli |
| author_facet | Vinod K. Rustgi Kapil Gupta Christopher Tait Abhishek Bhurwal Savan Kabaria Carolyn Catalano You Li Carlos D. Minacapelli |
| author_sort | Vinod K. Rustgi |
| collection | DOAJ |
| description | The economic and health care use burdens of Wilson’s disease (WD) are unknown. In this study, we aimed to quantify this health care resource use and economic burden. We performed a retrospective case‐control analysis of individuals in the Truven Health MarketScan Commercial Claims database (2007‐2017). Using propensity scores, 424 WD cases were matched 1:1 to chronic liver disease (CLD) controls without WD. Total and service‐specific parameters, expressed in monthly averages, were quantified for the 6‐month pre‐WD diagnosis versus the 12‐month period after diagnosis. Wilcoxon signed‐rank tests and McNemar tests were used to examine incremental differences in burden between cases and controls. Adjusted multivariable generalized linear regression models were used to compare health care burdens. Relative to the 6‐month pre‐WD diagnosis, the 12 months after diagnosis had more claims per patient (2.87 vs. 3.35; P < 0.0001) and increased per patient health care costs (US $2,089 vs. US $3,887; P < 0.0001). WD cases incurred US $1,908 more in total unadjusted costs compared to controls in the 12‐month postindex date monthly averages. The increase in claims was primarily due to outpatient visits (1.62 vs. 1.82) and pharmaceutical claims (1.11 vs. 1.37). Cases also had higher health care costs for inpatient admissions (US $559 vs. US $1,264), outpatient visits (US $770 vs. US $1,037), and pharmaceutical claims (US $686 vs. US $1,489). Conclusion: WD is associated with significant health care cost and use burdens driven by increased inpatient admissions, outpatient visits, and pharmaceutical claims. |
| first_indexed | 2024-04-10T18:02:02Z |
| format | Article |
| id | doaj.art-ce5c7f31d1b946d1b6e6dc4650c747af |
| institution | Directory Open Access Journal |
| issn | 2471-254X |
| language | English |
| last_indexed | 2024-04-10T18:02:02Z |
| publishDate | 2022-02-01 |
| publisher | Wolters Kluwer Health/LWW |
| record_format | Article |
| series | Hepatology Communications |
| spelling | doaj.art-ce5c7f31d1b946d1b6e6dc4650c747af2023-02-02T15:25:15ZengWolters Kluwer Health/LWWHepatology Communications2471-254X2022-02-016238939810.1002/hep4.1812Wilson’s Disease: An Analysis of Health Care Use and Cost Burden of Commercially Insured Adults in the United StatesVinod K. Rustgi0Kapil Gupta1Christopher Tait2Abhishek Bhurwal3Savan Kabaria4Carolyn Catalano5You Li6Carlos D. Minacapelli7Division of Gastroenterology and Hepatology Rutgers Robert Wood Johnson Medical School New Brunswick NJ USADivision of Gastroenterology and Hepatology Rutgers Robert Wood Johnson Medical School New Brunswick NJ USADivision of Gastroenterology and Hepatology Rutgers Robert Wood Johnson Medical School New Brunswick NJ USADivision of Gastroenterology and Hepatology Rutgers Robert Wood Johnson Medical School New Brunswick NJ USAInternal Medicine Robert Wood Johnson Medical SchoolRutgers Biomedical and Health SciencesRutgers University New Brunswick NJ USADivision of Gastroenterology and Hepatology Rutgers Robert Wood Johnson Medical School New Brunswick NJ USADivision of Gastroenterology and Hepatology Rutgers Robert Wood Johnson Medical School New Brunswick NJ USADivision of Gastroenterology and Hepatology Rutgers Robert Wood Johnson Medical School New Brunswick NJ USAThe economic and health care use burdens of Wilson’s disease (WD) are unknown. In this study, we aimed to quantify this health care resource use and economic burden. We performed a retrospective case‐control analysis of individuals in the Truven Health MarketScan Commercial Claims database (2007‐2017). Using propensity scores, 424 WD cases were matched 1:1 to chronic liver disease (CLD) controls without WD. Total and service‐specific parameters, expressed in monthly averages, were quantified for the 6‐month pre‐WD diagnosis versus the 12‐month period after diagnosis. Wilcoxon signed‐rank tests and McNemar tests were used to examine incremental differences in burden between cases and controls. Adjusted multivariable generalized linear regression models were used to compare health care burdens. Relative to the 6‐month pre‐WD diagnosis, the 12 months after diagnosis had more claims per patient (2.87 vs. 3.35; P < 0.0001) and increased per patient health care costs (US $2,089 vs. US $3,887; P < 0.0001). WD cases incurred US $1,908 more in total unadjusted costs compared to controls in the 12‐month postindex date monthly averages. The increase in claims was primarily due to outpatient visits (1.62 vs. 1.82) and pharmaceutical claims (1.11 vs. 1.37). Cases also had higher health care costs for inpatient admissions (US $559 vs. US $1,264), outpatient visits (US $770 vs. US $1,037), and pharmaceutical claims (US $686 vs. US $1,489). Conclusion: WD is associated with significant health care cost and use burdens driven by increased inpatient admissions, outpatient visits, and pharmaceutical claims.https://doi.org/10.1002/hep4.1812 |
| spellingShingle | Vinod K. Rustgi Kapil Gupta Christopher Tait Abhishek Bhurwal Savan Kabaria Carolyn Catalano You Li Carlos D. Minacapelli Wilson’s Disease: An Analysis of Health Care Use and Cost Burden of Commercially Insured Adults in the United States Hepatology Communications |
| title | Wilson’s Disease: An Analysis of Health Care Use and Cost Burden of Commercially Insured Adults in the United States |
| title_full | Wilson’s Disease: An Analysis of Health Care Use and Cost Burden of Commercially Insured Adults in the United States |
| title_fullStr | Wilson’s Disease: An Analysis of Health Care Use and Cost Burden of Commercially Insured Adults in the United States |
| title_full_unstemmed | Wilson’s Disease: An Analysis of Health Care Use and Cost Burden of Commercially Insured Adults in the United States |
| title_short | Wilson’s Disease: An Analysis of Health Care Use and Cost Burden of Commercially Insured Adults in the United States |
| title_sort | wilson s disease an analysis of health care use and cost burden of commercially insured adults in the united states |
| url | https://doi.org/10.1002/hep4.1812 |
| work_keys_str_mv | AT vinodkrustgi wilsonsdiseaseananalysisofhealthcareuseandcostburdenofcommerciallyinsuredadultsintheunitedstates AT kapilgupta wilsonsdiseaseananalysisofhealthcareuseandcostburdenofcommerciallyinsuredadultsintheunitedstates AT christophertait wilsonsdiseaseananalysisofhealthcareuseandcostburdenofcommerciallyinsuredadultsintheunitedstates AT abhishekbhurwal wilsonsdiseaseananalysisofhealthcareuseandcostburdenofcommerciallyinsuredadultsintheunitedstates AT savankabaria wilsonsdiseaseananalysisofhealthcareuseandcostburdenofcommerciallyinsuredadultsintheunitedstates AT carolyncatalano wilsonsdiseaseananalysisofhealthcareuseandcostburdenofcommerciallyinsuredadultsintheunitedstates AT youli wilsonsdiseaseananalysisofhealthcareuseandcostburdenofcommerciallyinsuredadultsintheunitedstates AT carlosdminacapelli wilsonsdiseaseananalysisofhealthcareuseandcostburdenofcommerciallyinsuredadultsintheunitedstates |